Medical Communications
FDA approves Glaukos’ iDose TR treatment for glaucoma disease
December 15, 2023 Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma
FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
December 14, 2023 Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial
FDA grants Kyverna Therapeutics fast track designation for myasthenia gravis treatment
December 14, 2023 Medical Communications FDA, Kyverna Therapeutics, Musculo-skeletal disorder, myasthenia gravis
Merck and Moderna initiate phase 3 study of NSCLC treatment
December 13, 2023 Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial
PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research
December 13, 2023 Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM
EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
December 12, 2023 Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma
GSK’s Jemperli approved in EU as treatment for endometrial cancer
December 11, 2023 Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
December 11, 2023 Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma
Regeneron shares data for multiple myeloma treatment
December 8, 2023 Medical Communications Cancer, Oncology, Regeneron, clinical trial
FDA approves Novartis’ Fabhalta for PNH treatment
December 6, 2023 Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH
British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing
December 5, 2023 Medical Communications British Medical Journal, Neurology, antidepressants, over-prescribing
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023 Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
GSK shares data from global shingles survey
December 1, 2023 Medical Communications GSK, Infections and infestations, data, shingles
FDA accepts NDA for Karuna’s schizophrenia treatment
November 30, 2023 Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia
Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device
November 30, 2023 Medical Communications Devices, FDA, Vivos Therapeutics, sleep apnea
Latest content
